A robust HTA/reimbursement strategy will form the basis for the submission, safeguard you in your preparations and increase the chances of a successful outcome of your HTA/reimbursement submission.
An HTA/reimbursement submission strategy for pharmaceuticals is about presenting your product in a way that is relevant to local policies in evaluating a product for reimbursement.
A reimbursement submission strategy should be prepared before any submission, enabling you to have clear plans and firm objectives as a basis for the HTA dossier development.
Important variables that will be taken into account are:
Timing of submissions
Specific evidence requirements in terms of clinical and or economic evidence
Potential HTA interaction
Identifying the relevant patient population for the submission
Advice on the best model (cost-min or cost-effectiveness)
Considerations regarding pricing and negotiation opportunities (e.g. tenders, managed entry agreements or three-party negotiations)
Arex will help you evade surprises and avoid delays in gaining reimbursement for your product. Our support will contribute to defining the opportunities and potential pitfalls involved in the HTA submission for your product.
We use a local landscape review as the basis for our strategy setting.
Susanne Schuurman
Staffan Thunell
Founding partner
BSc Economics and BA
Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from positions as Founder, Chairman, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.
